Free Trial Information
BioCentury | Apr 23, 2021
Product Development

Including SAB’s polyclonal therapy in NIAID COVID study could yield shield against variants

...Friday, FDA rescinded emergency use authorization of bamlanivimab monotherapy from Eli Lilly and Co. (NYSE:LLY) and AbCellera Biologics Inc. due...
Read More
BioCentury | Apr 20, 2021
Finance

Adagio raises $336M on promise of best-in-class COVID-19 mAb

...plus etesevimab. Lilly co-developed bamlanivimab with AbCellera Biologics Inc....
Read More
BioCentury | Apr 17, 2021
Product Development

April 16 COVID-19 Quick Takes: ACIP to reconvene over J&J’s vaccine on April 23; plus Gilead, Lilly-AbCellera and Sputnik V

...has shown greater efficacy against variants of SARS-CoV-2 than bamlanivimab alone. Lilly co-developed bamlanivimab with AbCellera Biologics Inc....
Read More
BioCentury | Apr 17, 2021
Product Development

How COVID vaccines might be causing blood clots with low platelets

...vaccines authorized for COVID-19: Convidecia from CanSino Biologics Inc....
...Tissue plasminogen activator Sandi Wong AstraZeneca plc Johnson & Johnson CanSino Biologics Inc. N.F...
Read More
BioCentury | Apr 14, 2021
Product Development

Adenoviral vector vaccines in development for COVID: Data Byte

...the Gamaleya Institute and Convidecia from CanSino Biologics Inc....
...in next-generation products. Selina Koch Johnson & Johnson AstraZeneca plc CanSino Biologics Inc. N.F...
Read More
BioCentury | Apr 7, 2021
Product Development

How COVID-19 brought China vaccine play CanSino onto the global stage

...countries, is the second authorized vaccine from CanSino Biologics Inc....
...vaccine in Phase I testing. Sandi Wong Convidecia (Ad5-nCoV) CanSino Biologics Inc. covid-19 cov19count cov19count...
Read More
BioCentury | Apr 6, 2021
Management Tracks

Memories of John Martin, plus AACR’s hot targets and a Bio€quity Europe preview: a BioCentury podcast

...companies starting immediately.Finally, in this week’s Deal in Focus, Cranmer and Li check in with AbCellera Biologics Inc....
...how fruitful AbCellera’s growing tool kit, built in part thanks to M&A, has become. Jeff Cranmer AbCellera Biologics Inc. Gilead...
Read More
BioCentury | Apr 6, 2021
Emerging Company Profile

Alloy: Building a better toolbox for biologics developers

...the model for free.A few biotechs have revealed their relationships with Alloy thus far: AbCellera Biologics Inc....
Read More
BioCentury | Apr 2, 2021
Management Tracks

BeiGene unveils new CFO; plus Precigen, Alphamab, Flagship, Melinta, Immunome and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) promoted SVP Julia Wang to CFO, effective June 30. Wang, who joined BeiGene last June, has held leadership roles in finance at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Johnson & Johnson (NYSE:JNJ) and...
Read More
BioCentury | Apr 1, 2021
Deals

Gilead again partners with AbCellera, forging multitarget deal that draws on biotech’s growing tool kit

...which it went public and gained an authorization for a COVID-19 program shared with Lilly.AbCellera Biologics Inc....
...to $30.71 at close. Its market cap now stands at $8.3 billion. Paul Bonanos Gilead Sciences Inc. AbCellera Biologics Inc....
Read More
Items per page:
1 - 10 of 1081
BioCentury | Apr 23, 2021
Product Development

Including SAB’s polyclonal therapy in NIAID COVID study could yield shield against variants

...Friday, FDA rescinded emergency use authorization of bamlanivimab monotherapy from Eli Lilly and Co. (NYSE:LLY) and AbCellera Biologics Inc. due...
Read More
BioCentury | Apr 20, 2021
Finance

Adagio raises $336M on promise of best-in-class COVID-19 mAb

...plus etesevimab. Lilly co-developed bamlanivimab with AbCellera Biologics Inc....
Read More
BioCentury | Apr 17, 2021
Product Development

April 16 COVID-19 Quick Takes: ACIP to reconvene over J&J’s vaccine on April 23; plus Gilead, Lilly-AbCellera and Sputnik V

...has shown greater efficacy against variants of SARS-CoV-2 than bamlanivimab alone. Lilly co-developed bamlanivimab with AbCellera Biologics Inc....
Read More
BioCentury | Apr 17, 2021
Product Development

How COVID vaccines might be causing blood clots with low platelets

...vaccines authorized for COVID-19: Convidecia from CanSino Biologics Inc....
...Tissue plasminogen activator Sandi Wong AstraZeneca plc Johnson & Johnson CanSino Biologics Inc. N.F...
Read More
BioCentury | Apr 14, 2021
Product Development

Adenoviral vector vaccines in development for COVID: Data Byte

...the Gamaleya Institute and Convidecia from CanSino Biologics Inc....
...in next-generation products. Selina Koch Johnson & Johnson AstraZeneca plc CanSino Biologics Inc. N.F...
Read More
BioCentury | Apr 7, 2021
Product Development

How COVID-19 brought China vaccine play CanSino onto the global stage

...countries, is the second authorized vaccine from CanSino Biologics Inc....
...vaccine in Phase I testing. Sandi Wong Convidecia (Ad5-nCoV) CanSino Biologics Inc. covid-19 cov19count cov19count...
Read More
BioCentury | Apr 6, 2021
Management Tracks

Memories of John Martin, plus AACR’s hot targets and a Bio€quity Europe preview: a BioCentury podcast

...companies starting immediately.Finally, in this week’s Deal in Focus, Cranmer and Li check in with AbCellera Biologics Inc....
...how fruitful AbCellera’s growing tool kit, built in part thanks to M&A, has become. Jeff Cranmer AbCellera Biologics Inc. Gilead...
Read More
BioCentury | Apr 6, 2021
Emerging Company Profile

Alloy: Building a better toolbox for biologics developers

...the model for free.A few biotechs have revealed their relationships with Alloy thus far: AbCellera Biologics Inc....
Read More
BioCentury | Apr 2, 2021
Management Tracks

BeiGene unveils new CFO; plus Precigen, Alphamab, Flagship, Melinta, Immunome and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) promoted SVP Julia Wang to CFO, effective June 30. Wang, who joined BeiGene last June, has held leadership roles in finance at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Johnson & Johnson (NYSE:JNJ) and...
Read More
BioCentury | Apr 1, 2021
Deals

Gilead again partners with AbCellera, forging multitarget deal that draws on biotech’s growing tool kit

...which it went public and gained an authorization for a COVID-19 program shared with Lilly.AbCellera Biologics Inc....
...to $30.71 at close. Its market cap now stands at $8.3 billion. Paul Bonanos Gilead Sciences Inc. AbCellera Biologics Inc....
Read More
Items per page:
1 - 10 of 1081